Transaction DateRecipientSharesTypePriceValue
15th January 2021Bob Rosenthal4,281Grant/award etc.$6.63$28,378.32
13th January 2021Bonnie H Anderson12,177Open or private sale$51.26$624,179.63
13th January 2021Bonnie H Anderson6,364Open or private sale$50.64$322,282.51
13th January 2021Bonnie H Anderson18,541Exercise of derivative$5.61$104,015.01
7th January 2021Marc A Kastner1,236Open or private sale$56.56$69,908.16
5th January 2021Bonnie H Anderson2,302Grant/award etc.$0.00
5th January 2021Cynthia M Friend2,302Grant/award etc.$0.00
5th January 2021Richard A Packer2,302Grant/award etc.$0.00
5th January 2021Bob Rosenthal2,302Grant/award etc.$0.00
5th January 2021Marc A Kastner2,302Grant/award etc.$0.00
Bruker Corporation
Bruker Corporation logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.

Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions. It operates through the Bruker Scientific Instruments (BSI), and Bruker Energy and Supercon Technologies (BEST) segments. The BSI segment comprises of Bruker BioSpin Group, Bruker CALID Group, and the Brukers Nano Group. The BEST segment designs, manufactures, and distributes superconducting materials, primarily metallic low temperature superconductors.

Ticker: BRKR
Sector: Healthcare
Industry: Medical Devices
SEC Central Index Key (CIK): 1109354
Employees: 6870
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $747 M (10%)
Inventory, Net: $665 M (0%)
Other Assets, Current: $170 M (0%)
Assets, Current: $2 B (8%)
Property, Plant and Equipment, Net: $336 M (9%)
Assets: $3 B (0%)
Accounts Payable, Current: $119 M (0%)
Liabilities, Current: $750 M (16%)
Long-term Debt, Excluding Current Maturities: $924 M (0%)
Other Liabilities, Noncurrent: $320 M (-2%)
Common Stock, Shares, Issued: $174 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $14 M (-47%)
Treasury Stock, Value: $6 Th (9%)
Treasury Stock, Shares: $206 M (6%)
Stockholders' Equity (Parent): $897 M (-1%)
Liabilities and Equity: $3 B (6%)
Revenue: $425 M (0%)
Gross Margin: $186 M (-50%)
Research and Development: $44 M (-52%)
Restructuring Charges: $2 M (-60%)
Operating Income/Loss: $38 M (0%)
Other Income, net: $7 M (-30%)
Provision for income taxes: $7 M (0%)
EPS (basic): $0.16 (0%)
EPS (diluted): $0.16 (0%)